Immunogenic cell death in cancer immunotherapy

Cancer immunotherapy has been acknowledged as a new paradigm for cancer treatment, with notable therapeutic effects on certain cancer types. Despite their significant potential, clinical studies over the past decade have revealed that cancer immunotherapy has low response rates in the majority of so...

Full description

Saved in:
Bibliographic Details
Published in:BMB reports 2023-05, Vol.56 (5), p.275-286
Main Authors: Minji Choi, Jisoo Shin, Chae-eun Lee, Joo-yoon Chung, Minji Kim, Xiuwen Yan, Wen-hao Yang, Jong-ho Cha
Format: Article
Language:Korean
Subjects:
Cancer immunotherapy
Cold tumor
Ferroptosis
Hot tumor
Immunogenic cell death
Necroptosis
Pyroptosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunotherapy has been acknowledged as a new paradigm for cancer treatment, with notable therapeutic effects on certain cancer types. Despite their significant potential, clinical studies over the past decade have revealed that cancer immunotherapy has low response rates in the majority of solid tumors. One of the key causes for poor responses is known to be the relatively low immunogenicity of solid tumors. Because most solid tumors are immune desert ‘cold tumors’ with antitumor immunity blocked from the onset of innate immunity, combination therapies that combine validated T-based therapies with approaches that can increase tumor-immunogenicity are being considered as relevant therapeutic options. This review paper focuses on immunogenic cell death (ICD) as a way of enhancing immunogenicity in tumor tissues. We will thoroughly review how ICDs such as necroptosis, pyroptosis, and ferroptosis can improve anti-tumor immunity and outline clinical trials targeting ICD. Finally, we will discuss the potential of ICD inducers as an adjuvant for cancer immunotherapy. [BMB Reports 2023; 56(5): 275-286]
ISSN:1976-6696
1976-670X